Page last updated: 2024-11-04

suberoyl bis-hydroxamic acid and Carcinoma, Medullary

suberoyl bis-hydroxamic acid has been researched along with Carcinoma, Medullary in 1 studies

suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor

Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ning, L1
Greenblatt, DY1
Kunnimalaiyaan, M1
Chen, H1

Other Studies

1 other study available for suberoyl bis-hydroxamic acid and Carcinoma, Medullary

ArticleYear
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
    The oncologist, 2008, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Medullary; Caspas

2008